<DOC>
	<DOCNO>NCT01570790</DOCNO>
	<brief_summary>The purpose study assess safety , bioactivity , maximal tolerate dose repeat weekly intravenous infusion combretastatin A-4 phosphate ( CA4P ) patient neovascular age-related macular degeneration</brief_summary>
	<brief_title>Combretastatin A4 Phosphate Patients With Neovascular Age-Related Macular Degeneration</brief_title>
	<detailed_description>The study design single escalate dose cohort five subject . Escalation next cohort base presence one subject dose limit toxicity ( DLT ) . The first cohort receive 27 mg/m2 intravenous infusion CA4P , 36mg/m2 second cohort , 45mg/m2 third cohort . CA4P infuse baseline every week total 4 dos . Follow visit schedule week 8 12 . Safety data collect 12-week duration study assess use common terminology criterion adverse event ( CTCAE v3.0 ) . Bioactivity data assess measure change best correct visual acuity , change central retinal thickness measure Optical coherence tomography , change amount leakage fluorescein angiography . DLTs define specific event consider probably definitely related CA4P . Major DLTs include QTc interval ≥ 500 msec ( base measurement provide core laboratory ECG analysis ) , Grade-2 great ventricular arrhythmia , unexplained syncope , Grade-3 great toxicity , delayed recovery postpone re-treatment &gt; 14 day , ocular toxicity keratopathy , uveitis , optic neuropathy , retinopathy , discretion investigator .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Combretastatin</mesh_term>
	<mesh_term>Fosbretabulin</mesh_term>
	<criteria>1 . Age 50 year old ; 2 . 12lead electrocardiogram ( ECG ) perform least 2 week less 4 week prior entry study show QTc &lt; 440 evidence current prior myocardial ischemia , infarction significant arrhythmia determine review signature cardiologist . 3 . Adequate bone marrow function : Absolute granulocyte count ≥1500 cells/mm3 ; Platelet count ≥100,000 cells/mm3 ; Hemoglobin ≥9.0gm/ dL ; 4 . PT/PTT within institution upper limit normal ( ULN ) INR &lt; 1.1 ; 5 . Adequate hepatic function : Total bilirubin within institution ULN ; Alanine aspartate aminotransferase ( ALT/AST ) &lt; 3 time institutional ULN ; 6 . Adequate renal function : serum creatinine ≤2.0 mg/dL ; 7 . Ophthalmic criterion : 1 . Best correct visual acuity study eye ≤20/40 ≥20/800 fellow eye . 2 . Subfoveal choroidal neovascularization ( illustrated fluorescein angiography ) secondary agerelated macular degeneration , total lesion size ≤12 total disc area , least 50 % must active CNV . 3 . Subretinal hemorrhage ≤50 % total lesion size ; 4 . For patient minimally classic purely occult CNV , must document evidence ≥2 line vision loss ( ETDRS ) previous 12 week ; 5 . Clear ocular medium adequate papillary dilatation permit good quality stereoscopic fundus photography ; 8 . Male fertile patient must abstain sexual intercourse use effective birth control ; 9 . Women must postmenopausal least 12 month prior study entry , surgically sterile , must use two form effective contraception . 10 . Able return study visit within require visit window ; 11 . Be able give write informed consent . 1 . Previous subfoveal thermal laser therapy ; 2 . Any subfoveal scarring atrophy , &gt; 25 % total lesion size make scar atrophy ; 3 . Significant medium opacity , include cataract , interfere visual acuity , assessment toxicity , fundus photography ; 4 . Presence cause choroidal neovascularization , include pathologic myopia ( spherical equivalent ≥8.0 diopter , axial length ≥25mm ) , ocular histoplasmosis syndrome , angioid streak , choroidal rupture , multifocal choroiditis uveitic entity ; 5 . Any condition might interfere assessment progression CNV ; 6 . Any intraocular surgery study eye within 12 week screen study ; 7 . Other treatment AMD study eye within 12 week prior screen ; 8 . Known allergy fluorescein ; 9 . Any current history significant gastrointestinal , oral , nasal bleeding ; 10 . Serious intercurrent infection nonmalignant medical illness uncontrolled whose control may jeopardize complication therapy ; 11 . Grade 2 ( CTC v.3.0 ) great preexist peripheral neuropathy ; 12 . Psychiatric disorder condition render patient incapable comply requirement protocol ; 13 . Pregnant breastfeeding woman ; 14 . History angina , myocardial infarction , CHF , noncontrolled atrial arrhythmia clinically significant arrhythmia include conduction abnormality , nodal junctional arrhythmia dysrhythmias , sinus bradycardia tachycardia , supraventricular arrhythmia , atrial fibrillation flutter , syncope vasovagal episode ; 15 . Abnormal cardiac stress test ; 16 . Uncontrolled hypertension ( consistently &gt; 150/100mmHg irrespective medication ) ; 17 . Uncontrolled hypokalemia and/or hypomagnesemia ; 18 . ECG evidence prior myocardial infarction , QTc &gt; 450 msec clinically significant abnormality ; 19 . Drug ( ) know prolong QTc interval ; 20 . Patients condition associate QTc prolongation ; 21 . Any investigational drug device within 4 week prior screen ; 22 . Decreased ejection fraction ≤50 % prior myocardial infarction .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>